Institutional members access full text with Ovid®

Share this article on:

Pediatric genitourinary tumors

McLean, Thomas W; Castellino, Sharon M

doi: 10.1097/CCO.0b013e3282f8b053
Genitourinary system: Edited by Frank M. Torti

Purpose of review We will review the recent (2006/2007) literature on pediatric genitourinary tumors.

Recent findings The WTX gene is now the most common known gene mutatation in Wilms' tumor. It acts as a tumor suppressor gene and may play a role in other malignancies. Current clinical trials have incorporated the loss of heterozygosity of 1p and 16q along with age, tumor size, stage, and response to therapy to risk stratify therapy. The PAX3–FOX01 gene fusion and the IGF-1R-signaling and mTOR-signaling pathways are implicated in rhabdomyosarcoma biology, and hence are promising therapeutic targets for this tumor.

Summary Progress is being made in understanding the pathogenesis of genitourinary tumors in children, and the prognosis for these children continues to improve. Current treatment strategies are focused on improving event-free survival while decreasing late effects from therapy.

Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Correspondence to Dr Thomas W. McLean MD, Department of Pediatrics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA Tel: +1 336 716 4085; fax: +1 336 716 3010; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.